HIV patients cured by stem cell transplantation.
| Patient | HIV (D)ART (T) | 2nd Disease | Conditioning | Transplantation | Remarks | Reference |
|---|---|---|---|---|---|---|
| Berlin | 1995 (D), 2003 (T) | AML, 2007 | Chemotherapy, total body irradiation (200 cGy) | 2× CCR5Δ32/Δ32, allo-HSCT, blood stem cells | Died in 2020 from AML | [71] |
| London | 2003 (D), 2012 (T) | Hodgkin lymphoma, 2012 | Alemtuzumab, cyclosporine A, methotrexate | CCR5Δ32/Δ32, allo-HSCT, bone marrow | ART post-transplantation for 510 days | [72] |
| Düsseldorf | 2008 (D), 2010 (T) | AML, 2011 | Reduced-intensity conditioning | CCR5Δ32/Δ32, allo-HSCT, blood stem cells | ART post-transplantation for 69 months | [73] |
| New York | 2013 (D), 2017 (T) | AML, 2017 | Fludarabine, melphalan, total body irradiation, anti-thymocyte globulin | CCR5Δ32/Δ32, haplocord and blood stem cells | ART post-transplantation for 37 months | [69] |
| City of Hope | 1988 (D), 1997 (T) | AML, 2019 | Fludarabine, melphalan | CCR5Δ32/Δ32, allo-HSCT, blood stem cells | ART post-transplantation for 25 months | [75] |
| Geneva | 1990 (D), 1990 (T) | Myeloid sarcoma, 2018 | High intensity, irradiation (8 Gray) | CCR5WT/WT, allo-HSCT, blood stem cells, 2018 | ART + ruxolitinib until 11.2021 | [76] |
| Berlin #2 | 2009 (D) | AML, 2015 | Total body irradiation, intensive chemotherapy | CCR5Δ32/WT, allo-HSCT, bone marrow, 2015 | ART post-transplantation until 2018 | [77] |
| NN | 1999 (D) | AML, 2020 | Cyclophosphamide, irradiation (200 cGy) | CCR5Δ32/Δ32 allo-HSCT, 2020 | Analytic treatment interruption in 10.2023 | [78] |
HIV(D): year of HIV diagnosis; ART(T): start of antiretroviral therapy; AML: acute myeloid leukemia; allo-HSCT: allogeneic hematopoietic stem cell transplantation; WT: wild type.
WK: Conceptualization, Investigation, Methodology, Supervision, Visualization, Writing—original draft, Writing—review & editing. The author read and approved the submitted version.
The author declares that there are no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.